Fetal anaemia as a cause of fetal injury: Diagnosis and management

Current Opinion in Obstetrics and Gynecology

Volumn 18, Issue 2, 2006, Pages 100-105

  Lin, Wai Chan ^a   Tze, Kin Lau ^a   Chung, Tony Kwok Hung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fetal anaemia; Intrauterine transfusion; Parvovirus infection; Rhesus isoimmunization; Thalassaemia

Indexed keywords

DNA; RHESUS D ANTIBODY;

ANEMIA; BLOOD FLOW VELOCITY; BLOOD GROUP RH; CLINICAL PRACTICE; ERYTHEMA INFECTIOSUM; FETUS; FETUS ANEMIA; FETUS DISEASE; FETUS ECHOGRAPHY; FETUS INJURY; FETUS WASTAGE; GENOTYPE; HIGH RISK PREGNANCY; HUMAN; INJURY; INTRAUTERINE BLOOD TRANSFUSION; MATERNAL BLOOD; MIDDLE CEREBRAL ARTERY; PRENATAL SCREENING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHESUS ISOIMMUNIZATION; THALASSEMIA;

BLOOD TRANSFUSION, INTRAUTERINE; ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM; THALASSEMIA; ULTRASONOGRAPHY, PRENATAL;

EID: 33646515352     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000192981.69352.dc     Document Type: Review

References (58)

1. National Institute for Clinical Excellence. Technology appraisal guidance 41. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. London: NICE; 2002.
2. Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunization (Cochrane Review). The Cochrane Library 2005, Issue 4. Chichester, UK: John Wiley and Sons. A Cochrane database review summarizing the current evidence supporting the efficacy of routine antenatal anti-D prophylaxis.
3. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43:1661-1666.
4. Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R. Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 1997; 89:272-275.
5. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350:485-487.
6. Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42:1079-1085.
7. Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann N Y Acad Sci 2004; 1022:119-123. This report describes the quality control and the outcome of fetal D typing using free fetal DNA in maternal plasma.
8. Daniels G, Finning K, Martin P, Soothill P. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004; 87:225-232. This paper compares the various noninvasive methods of fetal blood group genotyping and confirms the benefits of introduction of fetal blood group genotyping by a reduction in the need for invasive diagnostic methods.
9. Van der Schoot CE, Tax GH, Rijnders RJ, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003; 17:31-44.
10. Divakaran TG, Waugh J, Clark TJ, et al. Noninvasive techniques to detect fetal anemia due to red blood cell alloimmunization: a systematic review. Obstet Gynecol 2001; 98:509-517.
11. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9-14.
12. Bullock R, Martin WL, Coomarasamy A, Kilby MD. Prediction of fetal anemia in pregnancies with red-cell alloimmunization: comparison of middle cerebral artery peak systolic velocity and amniotic fluid OD450. Ultrasound Obstet Gynecol 2005; 25:331-334. This paper directly compares the two screening modalities to the gold standard of fetal blood sampling and shows that both are comparable in terms of sensitivity and specificity. MCA PSV is preferred, however, because of its noninvasiveness.
13. Stefos T, Cosmi E, Detti L, Mari G. Correction of fetal anemia on the middle cerebral artery peak systolic velocity. Obstet Gynecol 2002; 99:211-215.
14. Mari G, Abuhamad AZ, Cosmi E, et al. Middle cerebral artery peak systolic velocity: technique and variability. J Ultrasound Med 2005; 24:425-430. This paper provides a framework for the assessment of techniques involved in the accurate measurement of the MCA PSV by comparing the reproducibility in different parts of the middle cerebral arteries.
15. Detti L, Mari G. Noninvasive diagnosis of fetal anemia. Clin Obstet Gynecol 2003; 46:923-930.
16. Detti L, Mari G, Akiyama M, et al. Longitudinal assessment of the middle cerebral artery peak systolic velocity in healthy fetuses and in fetuses at risk for anemia. Am J Obstet Gynecol 2002; 187:937-939.
17. Rightmire DA, Nicolaides KH, Rodeck CH, Campbell S. Fetal blood velocities in Rh isoimmunization: relationship to gestational age and to fetal hematocrit. Obstet Gynecol 1986; 68:233-236.
18. Harrington K, Fayyad A, Nicolaides KH. Predicting the severity of fetal anemia using time-domain measurement of volume flow in the fetal aorta. Ultrasound Obstet Gynecol 2004; 23:437-441. This prospective observational study assesses the feasibility and problems associated with this alternative Doppler ultrasound marker other than MCA PSV.
19. Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol 1996; 174:547-551.
20. Leggat HM, Gibson JM, Barron SL, Reid MM. Anti-Kell in pregnancy. Br J Obstet Gynaecol 1991; 98:162-165.
21. van Dongen H, Klumper FJ, Sikkel E, et al. Non-invasive tests to predict fetal anemia in Kell-alloimmunized pregnancies. Ultrasound Obstet Gynecol 2005; 25:341-345. This prospective study on 27 fetuses at-risk of Kell alloimmunization confirms the role of MCA PSV, and extends its clinical use in addition to rhesus alloimmunization.
22. Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta 1999; 20:103-108.
23. Yaegashi N, Niinuma T, Chisaka H, et al. Serologic study of human parvovirus B19 infection in pregnancy in Japan. J Infect 1999; 38:30-35.
24. Morey AL, Ferguson DJ, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis. J Pathol 1993; 169:213-220.
25. Komischke K, Searle K, Enders G. Maternal serum alpha-fetoprotein and human chorionic gonadotropin in pregnant women with acute parvovirus B19 infection with and without fetal complications. Prenat Diagn 1997; 17:1039-1046.
26. Lim WL, Wong KF, Lau CS. Parvovirus B19 infection in Hong Kong. J Infect 1997; 35:247-249.
27. Ooi SL, Hooi PS, Chua BH, et al. Seroprevalence of human parvovirus B19 infection in an urban population in Malaysia. Med J Malaysia 2002; 57:97-103.
28. Gay NJ, Hesketh LM, Cohen BJ, et al. Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy? Commun Dis Rep CDR Rev 1994; 4:R104-R107.
29. Skjoldebrand-Sparre L, Fridell E, Nyman M, Wahren B. A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstet Gynecol Scand 1996; 75:336-339.
30. Harger JH, Adler SP, Koch WC, Harger GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998; 91:413-420.
31. Jordan JA. Identification of human parvovirus B19 infection in idiopathic non-immune hydrops fetalis. Am J Obstet Gynecol 1996; 174:37-42.
32. Delle Chiaie L, Buck G, Grab D, Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18:232-236.
33. Dieck D, Schild RL, Hansmann M, Eis-Hubinger AM. Prenatal diagnosis of congenital parvovirus B19 infection: value of serological and PCR techniques in maternal and fetal serum. Prenat Diagn 1999; 19:1119-1123.
34. Saldanha J, Lelie N, Yu MW, Heath A, B19 Collaborative Study Group. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002; 82:24-31.
35. Ferguson M, Heath A. Report of a collaborative study to calibrate the Second International Standard for parvovirus B19 antibody. Biologicals 2004; 32:207-212. This paper outlines the preparation of the second International Standard for parvovirus B19 IgG, human serum and calibrates it in IU.
36. Xu XM, Zhou YQ, Luo GX, et al. The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol 2004; 57:517-522. This epidemiological study provides up-to-date information on the prevalence and mutation spectrum of thalassaemia in southeast Asia, illustrating the higher percentage of the southeast Asian type of deletion (SEA), accounting for 48.54% of all alpha thalassaemias.
37. Prior JF, Bittles AH, Erber WN. A community profile of alpha thalassaemia in Western Australia. Community Genet 2004; 7:211-215. This epidemiological study demonstrates the effects of immigration on the increase in the burden of thalassaemia in those countries of low prevalence.
38. Cao A. Results of programmes for antenatal detection of thalassemia in reducing the incidence of the disorder. Blood Rev 1987; 1:169-176.
39. Christianson A, Streetly A, Darr A. Lessons from thalassaemia screening in Iran. Br Med J 2004; 329:1115-1117.
40. Haddow JE. Couple screening to avoid thalassemia: successful in Iran and instructive for us. J Med Screen 2005; 12:55-56.
41. Elton P. Learning from low income countries: thalassaemia screening in Iran provides evidence for programme in Lancashire. Br Med J 2005; 330:478-479.
42. Samavat A, Modell B. Iranian national thalassaemia screening programme. Br Med J 2004; 329:1134-1137. This paper outlines the implementation and successful outcome of a national thalassaemia screening programme in a low resource country with abundant lessons to learn from for both low and high resource countries.
43. Liao C, Mo QH, Li J, et al. Carrier screening for alpha- and beta-thalassemia in pregnancy: the results of an 11-year prospective program in Guangzhou Maternal and Neonatal hospital. Prenat Diagn 2005; 25:163-171. This epidemiological study examines the carrier screening and prenatal diagnosis in one of the largest hospital in Guangzhou, China and illustrates the effectiveness of hospital-based screening programme in reducing severe thalassaemia births.
44. Leung WC, Oepkes D, Seaward G, Ryan G. Serial sonographic findings of four fetuses with homozygous alpha-thalassemia-1 from 21 weeks onwards. Ultrasound Obstet Gynecol 2002; 19:56-59.
45. Lam YH, Tang MH, Lee CP, Tse HY. Cardiac blood flow studies in fetuses with homozygous alpha-thalassemia-1 at 12-13 weeks of gestation. Ultrasound Obstet Gynecol 1999; 13:48-51.
46. Ghosh A, Tang MH, Lam YH, et al. Ultrasound measurement of placental thickness to detect pregnancies affected by homozygous alpha-thalassaemia-1. Lancet 1994; 344:988-989.
47. Lam YH, Tang MH, Lee CP, Tse HY. Prenatal ultrasonographic prediction of homozygous type 1 alpha-thalassemia at 12 to 13 weeks of gestation. Am J Obstet Gynecol 1999; 180:148-150.
48. Lam YH, Tang MH. Middle cerebral artery Doppler study in fetuses with homozygous alpha-thalassaemia-1 at 12-13 weeks of gestation. Prenat Diagn 2002; 22:56-58.
49. Hui PW, Lam YH, Chen M, et al. Attitude of at-risk subjects towards preimplantation genetic diagnosis of alpha- and beta-thalassaemias in Hong Kong. Prenat Diagn 2002; 22:508-511.
50. Monni G, Cau G, Usai V, et al. Preimplantation genetic diagnosis for beta-thalassaemia: the Sardinian experience. Prenat Diagn 2004; 24:949-954. This reviews 23 couples at risk of beta thalassaemia undergoing genetic counselling and preimplantation genetic diagnosis, with 95% successful embryo biopsy and 78% successful genetic diagnosis.
51. Jiao ZX, Zhuang GL, Zhou CQ, et al. Birth of healthy children after pre-implantation diagnosis of beta-thalassemia. Chin Med J (Engl) 2004; 117:483-487. This report demonstrates the efficiency and accuracy of pre-implantation genetic diagnosis and the experience in China.
52. Piyamongkol W, Harper JC, Delhanty JD, Wells D. Preimplantation genetic diagnostic protocols for alpha- and beta-thalassaemias using multiplex fluorescent PCR. Prenat Diagn 2001; 21:753-759.
53. Pattison NS, Roberts AB, Mantell N. Intrauterine fetal transfusions 1963-90. Ultrasound Obstet Gynecol 1992; 2:329-332.
54. Van Kamp IL, Klumper FJ, Meerman RH, et al. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999. Acta Obstet Gynecol Scand 2004; 83:731-737. This retrospective cohort study examines the pregnancy outcome of 210 fetuses undergoing 593 intrauterine transfusions in the Netherlands, demonstrating the importance of early diagnosis and referral to centres with expertise in intrauterine transfusions.
55. Rodeck CH, Nicolaides KH, Warsof SL, et al. The management of severe rhesus isoimmunization by fetoscopic intravascular transfusions. Am J Obstet Gynecol 1984; 150:769-774.
56. Grab D, Paulus WE, Bommer A, et al. Treatment of fetal erythroblastosis by intravascular transfusions: outcome at 6 years. Obstet Gynecol 1999; 93:165-168.
57. Hudon L, Moise KJ Jr, Hegemier SE, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. Am J Obstet Gynecol 1998; 179:858-863.
58. Janssens HM, De Haan MJ, van Kamp IL, et al. Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism. J Pediatr 1997; 131:373-380.